🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
341

Quick answer

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  2. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  3. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  4. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  5. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  8. Iptacopan

    Novartis Pharmaceuticals

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule terminated

    1 trial

  9. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 small molecule active

    1 trial

  10. KAE609

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  11. KAE609

    Novartis Pharmaceuticals

    Cure Rate

    phase 2 small molecule completed

    1 trial

  12. KAF156

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  13. KAF156

    Novartis Pharmaceuticals

    Acute Uncomplicated Plasmodium Falciparum Malaria

    phase 2 small molecule completed

    1 trial

  14. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  15. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  16. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  17. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  18. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  19. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  20. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  21. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  22. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  23. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  24. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  25. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  26. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  27. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  28. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial

  29. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  30. MYCOPHENOLIC ACID , PREDNISONE, MYCOPHENOLATE SODIUM, PREDNISONE, MYCOPHENOLATE SODIUM, Placebo 0 mg hard gelatin capsule size 0 and size 2, (placebo to LNP023), METHYLPREDNISOLONE , IPTACOPAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, LNP023, Placebo to prednisone

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  31. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  32. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  33. Osilodrostat

    Novartis Pharmaceuticals

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  34. PARACETAMOL, Placebo to QUC398 150 mg/1 mL Solution for injection, QUC398, Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial

  35. PHE885

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  36. PKN605, Placebo to PKN605 50 mg film-coated tablets

    Novartis Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  37. PPY988A

    Novartis Pharmaceuticals

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial

  38. Panobinostat

    Novartis Pharmaceuticals

    Classical Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  39. Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  40. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  41. Placebo to BYL719 50 mg film-coated tablets (Light Yellow) Placebo to BYL719 125 mg film-coated tablets (Dark Yellow), BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  42. Placebo to LTP001 00mg hard gelatin capsule, LTP001, LTP001, Placebo to LTP001 00mg hard gelatin capsule

    Novartis Pharmaceuticals

    Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  43. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  44. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  45. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  46. QBW251

    Novartis Pharmaceuticals

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  47. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  48. Rapcabtagene autoleucel

    Novartis Pharmaceuticals

    ANCA Associated Vasculitis (AAV)

    phase 2 mab active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.